• Mashup Score: 2

    The FDA approved kallikrein inhibitor berotralstat for HAE in December 2020. A new study showed it’s superior to placebo in patients aged 12 years and older.

    Tweet Tweets with this article
    • FDA approved #plasma kallikrein inhibitor #berotralstat, in 2020, making it the first treatment available for the prevention of hereditary angioedema attacks in patients aged 12 years and up. Phase 3 trial results continue to show benefits. https://t.co/mBglu5VN5O